加拿大Nuvo Research Inc
Nuvo Research Inc. , ( 宻西沙加， Mississauga) ，一专门研发可 涂布或穿透皮肤之 加拿大药品开发公司
Nuvo Research Inc. (马克翰，Markham) 宣布公司因应将完成的关键性第三期临床成果，己网罗FDA专家群。公司的临床测试在2005年底会完成，而初步成果预定会在2006年一月公布。为了处理公司预定2006年中期在FDA申请新药上市许可作业(NDA)，公司已组成FDA顾问委员会。公司这次临床的测试药物是Pennsaid(R)，这是一种外用非固醇类消炎药物，主要用来治疗关节炎，目前在加拿大以及几个欧洲国家都已在贩卖。

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario with manufacturing facilities located in Varennes, Quebec and Wanzleben, Germany, and a research and development facility in San Diego, California.

Nuvo is focused on developing targeted therapeutic products designed to produce minimal side effects. The Company develops drugs based on two technology platforms: transdermal drug delivery and immune system regulation.
Nuvo markets two products Pennsaid®, a topical non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis and Oxoferin™, a topical wound healing agent.

Nuvo's primary focus is obtaining approval to market, and ultimately commercialize Pennsaid® in the U.S. market. Nuvo intends to leverage its transdermal drug delivery capabilities to create a portfolio of transdermal products targeting a variety of indications.